Heparin: Clinical Uses, Mechanism, and Adverse Effects

Heparin is an anticoagulant medication used to prevent and treat abnormal blood clot formation. It has important applications in respiratory care, critical care, cardiovascular medicine, extracorporeal membrane oxygenation, vascular monitoring, and arterial blood gas sampling.

Heparin works primarily by enhancing the activity of antithrombin, which inhibits key clotting factors such as thrombin and factor Xa. 

Although highly useful, heparin can also cause serious complications, particularly bleeding and heparin-induced thrombocytopenia. Safe use requires appropriate dosing, monitoring, specimen handling, and recognition of adverse effects.

What Is Heparin?

Heparin is a parenteral anticoagulant that reduces the ability of blood to form or extend clots. It belongs to a broader class of medications known as antithrombotic agents.

Antithrombotic drugs are generally divided into three groups:

• Anticoagulants
• Antiplatelet agents
• Thrombolytic agents

Anticoagulants, including heparin, interfere with the coagulation process and reduce fibrin formation. Antiplatelet medications primarily interfere with platelet activation and aggregation, while thrombolytic drugs actively break down fibrin within existing clots.

This distinction is important because heparin does not directly dissolve an established thrombus. Instead, it prevents additional clot formation and limits progression of the existing clot while the body gradually removes or reorganizes it.

Heparin has applications in venous thromboembolism, pulmonary embolism, acute coronary syndromes, extracorporeal membrane oxygenation, invasive vascular monitoring, arterial blood gas sampling, and certain cases of smoke inhalation injury.

Role of Heparin in Blood Coagulation

To understand how heparin works, it helps to review the normal coagulation process. When a blood vessel is injured, the normally anticoagulant endothelial surface becomes disrupted. Subendothelial tissue is exposed, and platelets begin adhering to the damaged area.

Von Willebrand factor helps platelets attach to the injured vessel wall. Activated platelets then release chemical mediators that recruit additional platelets and promote aggregation. Platelets also express glycoprotein IIb/IIIa receptors. Fibrinogen binds to these receptors and helps connect neighboring platelets.

At the same time, the coagulation cascade becomes activated. Both the intrinsic and extrinsic pathways eventually lead to activation of factor X. Activated factor X, known as factor Xa, participates in the conversion of prothrombin into thrombin.

Thrombin then converts fibrinogen into fibrin. Fibrin forms strands that stabilize the platelet plug and contribute to development of a durable blood clot. Heparin interferes with several parts of this process by enhancing the body’s natural anticoagulant mechanisms.

Mechanism of Action

The anticoagulant effect of heparin depends heavily on antithrombin, also called antithrombin III. Antithrombin is a naturally occurring protein produced by the liver. It inhibits several activated coagulation factors, including:

• Thrombin, or factor IIa
• Factor Xa
• Factor IXa
• Factor XIa
• Factor XIIa

Note: Heparin binds to antithrombin and greatly accelerates its ability to inhibit these clotting factors. The interaction between thrombin and antithrombin can be accelerated by approximately 1,000 times when heparin is present. This produces rapid anticoagulation.

Inhibition of Thrombin

Unfractionated heparin contains long polysaccharide chains. These chains allow heparin to bind both antithrombin and thrombin at the same time.

This creates a complex consisting of:

• Heparin
• Antithrombin
• Thrombin

Note: Formation of this complex allows antithrombin to rapidly inactivate thrombin. Because thrombin is responsible for converting fibrinogen into fibrin, inhibition of thrombin limits continued development of the fibrin clot.

Inhibition of Factor Xa

Heparin also promotes inhibition of factor Xa. Factor Xa plays an important role earlier in the coagulation pathway because it contributes to the formation of thrombin. Preventing factor Xa activity can therefore reduce production of large amounts of thrombin.

Unfractionated heparin has relatively balanced activity against factor Xa and factor IIa, with an approximate anti-Xa-to-anti-IIa activity ratio of 1:1. Low-molecular-weight heparins have proportionately greater activity against factor Xa.

Unfractionated Heparin

Unfractionated heparin, commonly abbreviated UFH, is the traditional form of heparin used in clinical care. It is a sulfated glycosaminoglycan composed of polysaccharide chains of different lengths.

UFH has an average molecular weight of approximately 12,000 Da, although individual molecules may range from about 5,000 to 30,000 Da. Many UFH chains are long enough to bind both thrombin and antithrombin simultaneously.

Clinical uses of unfractionated heparin include:

• Treatment of venous thromboembolism
• Treatment of pulmonary embolism
• Prevention of venous thromboembolism
• Anticoagulation during ECMO
• Selected cases of acute coronary syndrome
• Management of embolic disorders
• Prevention of clotting in certain vascular devices

Note: UFH may be given intravenously or subcutaneously depending on the indication. For acute thromboembolic disease, treatment frequently begins with an intravenous bolus followed by continuous intravenous infusion.

Low-Molecular-Weight Heparin

Low-molecular-weight heparins, commonly abbreviated LMWHs, are derived from unfractionated heparin but contain shorter polysaccharide chains.

Examples include:

• Enoxaparin
• Dalteparin

LMWH molecules have an average molecular weight of approximately 4,500 Da and generally contain shorter chains than unfractionated heparin.

Because many of these chains are too short to bind thrombin and antithrombin simultaneously, LMWH has less direct activity against thrombin. Its primary effect is enhancement of antithrombin-mediated inhibition of factor Xa.

For example, dalteparin has an anti-Xa-to-anti-IIa ratio of approximately 2:1, while the ratio for enoxaparin is even higher. This makes LMWH more selective for factor Xa inhibition than UFH.

UFH vs. Low-Molecular-Weight Heparin

Several important differences exist between unfractionated heparin and low-molecular-weight heparin. UFH binds extensively to plasma proteins, endothelial cells, platelet proteins, and other cellular components. This contributes to variable bioavailability and an unpredictable anticoagulant response.

As a result, therapeutic intravenous UFH usually requires laboratory monitoring. LMWH has more predictable absorption and bioavailability. It is typically administered subcutaneously once or twice daily and usually does not require routine laboratory monitoring.

The half-life also differs. UFH has a relatively short half-life, generally around 30 to 60 minutes. LMWH has a longer half-life of approximately 4 to 5 hours.

Because UFH wears off more rapidly and can be reversed more completely, it may be preferred when rapid discontinuation of anticoagulation could become necessary.

Heparin in Venous Thromboembolism

Venous thromboembolism includes deep venous thrombosis and pulmonary embolism. A deep venous thrombosis usually forms within a deep vein of the lower extremity or pelvis. A portion of the clot may break free and travel through the venous circulation to the lungs.

When this occurs, the clot becomes a pulmonary embolus. Pulmonary embolism may obstruct pulmonary blood flow and produce serious ventilation-perfusion abnormalities.

Heparin has traditionally been an important treatment for acute VTE because its anticoagulant effect begins quickly.

When VTE is strongly suspected and the risk of bleeding is acceptable, anticoagulation may be initiated before diagnostic testing has completely confirmed the diagnosis. This is done because untreated pulmonary embolism can deteriorate rapidly.

Heparin in Pulmonary Embolism

Pulmonary embolism obstructs blood flow through part of the pulmonary circulation. Affected areas of the lung may continue to receive ventilation even though perfusion is reduced or absent. This creates increased physiologic dead space.

Patients may respond by increasing respiratory rate and minute ventilation. Arterial blood gas results may show findings associated with hyperventilation, including respiratory alkalosis. Heparin does not remove the embolus directly.

Instead, anticoagulation helps prevent:

• Enlargement of the existing thrombus
• Formation of additional thrombi
• Additional embolization

Note: As clot formation is controlled, the body’s natural mechanisms gradually break down the existing thromboembolic material.

Heparin for VTE Prevention

Hospitalized patients often have an increased risk of developing DVT and pulmonary embolism.

Risk factors include:

• Immobility
• Critical illness
• Major surgery
• Trauma
• Spinal cord injury
• Previous VTE
• Heart failure
• Obesity
• Stroke
• Renal failure
• Hypercoagulable conditions

Patients at moderate or high risk may receive low-dose subcutaneous unfractionated heparin or low-molecular-weight heparin.

Mechanical measures may also be used, including early ambulation, compression stockings, intermittent pneumatic compression, and venous foot pumps. Mechanical prophylaxis is especially important when anticoagulant therapy cannot be administered because of bleeding risk.

Heparin in Acute Coronary Syndrome

Heparin may also be used in acute coronary syndrome. In NSTEMI, anticoagulation may be combined with antiplatelet and antianginal therapy.

Unfractionated heparin or low-molecular-weight heparin may be used as part of an antithrombin strategy. The purpose is to reduce additional clot formation within the coronary circulation. This is different from thrombolytic therapy, which attempts to break down an existing fibrin clot.

Patients with worsening ischemia, hemodynamic instability, refractory symptoms, or other evidence of deterioration may require urgent coronary intervention rather than continued medical therapy alone.

Heparin During ECMO

Extracorporeal membrane oxygenation requires the patient’s blood to circulate outside the body through tubing, cannulas, a pump, and an oxygenator. Blood normally reacts with these artificial surfaces.

Proteins adhere to the extracorporeal circuit and activate the coagulation system. Without anticoagulation, thrombi can develop inside the tubing or oxygenator.

These clots can:

• Impair blood flow
• Increase circuit resistance
• Decrease oxygenator function
• Damage circuit components
• Increase the risk of embolic complications

Note: Heparin is commonly administered before cannulation and continued during ECMO support. A loading dose may be given initially, followed by continuous maintenance therapy.

Monitoring Heparin During ECMO

Anticoagulation during ECMO requires a careful balance. Too little anticoagulation increases the risk of circuit thrombosis. Too much anticoagulation increases the risk of major bleeding.

Several tests may be used to monitor heparin activity and overall coagulation.

Activated Clotting Time

Activated clotting time, or ACT, is commonly used as a bedside monitoring test. Target ACT values vary by protocol, but ranges such as approximately 160 to 200 seconds may be used.

Targets may be lowered when significant bleeding occurs. Higher targets may sometimes be considered when blood flow through the extracorporeal circuit is reduced. ACT is affected by more than heparin concentration.

Potential influences include:

• Anemia
• Hypothermia
• Hemodilution
• Thrombocytopenia
• Platelet dysfunction
• Low fibrinogen
• Coagulation-factor abnormalities

Note: For this reason, ACT should not always be interpreted in isolation.

Anti-Factor Xa Monitoring

Anti-factor Xa testing can provide a more direct assessment of heparin’s anticoagulant activity. An anti-Xa target around 0.3 to 0.7 units/mL may be used in some ECMO protocols. Anti-Xa values may correlate more closely with heparin dosage than ACT values.

Antithrombin Levels

Because heparin depends on antithrombin to work effectively, antithrombin levels can also be important. Low antithrombin activity may cause apparent heparin resistance.

A patient may require unusually high heparin doses while still experiencing excessive clot formation. Treatment may involve antithrombin concentrate or fresh frozen plasma when clinically appropriate.

Heparin Resistance

Heparin resistance occurs when expected anticoagulation cannot be achieved despite administration of increasing amounts of heparin.

One important cause is reduced antithrombin activity. Because heparin requires antithrombin to inhibit coagulation factors effectively, inadequate antithrombin limits the response to heparin.

Heparin resistance may become particularly important during ECMO, where insufficient anticoagulation may result in visible circuit clot formation or impaired oxygenator function.

Assessment of antithrombin levels may therefore be appropriate when unexpectedly high heparin requirements occur.

Heparin in Arterial Blood Gas Sampling

Heparin also has an important laboratory role. Blood collected for arterial blood gas analysis must remain unclotted until it is analyzed. Heparinized syringes are commonly used for this purpose. Modern blood gas syringes often contain dry or lyophilized heparin.

Dry heparin is preferred because it provides anticoagulation without adding a significant volume of liquid that could dilute the specimen.

Sodium heparin or lithium heparin may also be used. Lithium heparin may be particularly useful when electrolyte measurements are performed on the same specimen.

Liquid Heparin and ABG Errors

Liquid heparin must be used carefully. If excessive liquid remains inside the syringe, the blood specimen can become diluted. This can alter measured blood gas values.

Potential changes include:

• Lower PCO₂
• Changes in pH
• Altered PO₂

Air contamination can produce additional errors, especially by increasing PO₂ and decreasing PCO₂. When liquid heparin is used, excess solution should therefore be expelled before the sample is collected.

Enough heparin should remain to prevent clotting, but the amount should be small enough to avoid meaningful dilution.

Mixing a Heparinized Blood Sample

Blood must be adequately mixed with the anticoagulant after collection. The syringe may be gently rolled or inverted so that heparin is distributed throughout the specimen.

Failure to mix the sample properly can allow small clots to form. Clots may interfere with blood gas analyzers and can make the specimen unreliable or unusable.

Proper anticoagulation, removal of air bubbles, correct mixing, and timely analysis are all important for maintaining specimen integrity.

Heparin and Arterial Lines

Indwelling arterial catheters are used for continuous blood pressure monitoring and repeated blood sampling. Blood can clot inside these catheters if stagnant blood remains within the tubing or catheter.

A pressurized flush system helps maintain catheter patency. Some systems have historically used heparinized saline. A solution containing small amounts of heparin may continuously flush the catheter and reduce the risk of thrombosis.

A partially clotted arterial catheter may produce a dampened pressure waveform or inaccurate blood pressure readings.

However, unnecessary exposure to heparin should be minimized when possible because even small exposures can contribute to complications such as heparin-induced thrombocytopenia in susceptible patients.

Drawing Blood From an Arterial Catheter

When a blood specimen is obtained from an arterial line, fluid within the catheter can contaminate the sample. The flush solution must therefore be cleared before collecting the analytical specimen.

A waste sample may first be withdrawn to remove residual flush solution from the catheter dead space. The blood gas specimen can then be collected using a heparinized syringe.

Excessive waste should be avoided because repeated laboratory sampling can contribute to significant blood loss, particularly in critically ill patients and infants.

Heparin in Capillary Blood Sampling

Heparinized capillary tubes may be used when collecting capillary blood specimens. This is particularly relevant in neonatal and pediatric patients.

Capillary samples may provide useful information about ventilation and acid-base status. However, they are less reliable for evaluating arterial oxygenation. The heparin within the capillary tube prevents the small specimen from clotting before laboratory analysis.

Aerosolized Heparin in Smoke Inhalation

Heparin may also be administered through the respiratory tract in selected patients with smoke inhalation injury.

Severe inhalation injury can damage the airway epithelium and produce:

• Airway edema
• Thick secretions
• Cellular debris
• Fibrin deposition
• Airway casts

These materials can obstruct the tracheobronchial tree and increase airway resistance. Aerosolized heparin may be combined with N-acetylcysteine and bronchodilator therapy.

N-acetylcysteine acts as a mucolytic, while aerosolized heparin is intended to reduce fibrin-related airway obstruction. Bronchodilators may be used when bronchospasm is present.

Airway clearance, humidification, and bronchoscopy may also be required depending on the severity of the injury.

Monitoring Unfractionated Heparin

The activated partial thromboplastin time, or aPTT, has traditionally been used to monitor therapeutic intravenous UFH. The aPTT is sensitive to changes in several coagulation factors affected by heparin.

A therapeutic goal may be expressed as approximately 1.5 to 2 times a laboratory control value, although modern protocols frequently use institution-specific ranges.

The exact relationship between aPTT and heparin concentration varies between laboratories and reagents. Anti-factor Xa testing may also be used to monitor unfractionated heparin in selected situations.

Monitoring Low-Molecular-Weight Heparin

Routine aPTT monitoring is not useful for LMWH. Because LMWH acts predominantly through factor Xa inhibition, anti-factor Xa testing is more appropriate when laboratory assessment is required. Routine testing is not generally necessary because LMWH has relatively predictable pharmacokinetics.

Monitoring may be considered in selected patients, including those with:

• Significant renal dysfunction
• Extreme obesity
• Very low body weight
• Other conditions that may alter drug handling

Bleeding Complications

Bleeding is the most important adverse effect of heparin. The severity can range from mild bruising or hematoma formation to life-threatening internal hemorrhage.

Possible bleeding sites include:

• Gastrointestinal tract
• Urinary tract
• Surgical sites
• Catheter insertion sites
• Intracranial space
• Retroperitoneal space

Note: Patients receiving heparin should be assessed for clinical evidence of bleeding as well as changes in hemoglobin and hematocrit. Significant bleeding may require discontinuation of heparin and possible administration of a reversal agent.

Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia, or HIT, is one of the most important complications associated with heparin therapy. Two forms are commonly described.

HIT Type 1

HIT type 1 is a mild, early decrease in platelet count. It usually occurs soon after heparin therapy begins and is generally transient.

The platelet count may decrease modestly without producing serious clinical consequences. Heparin therapy may not always need to be stopped in this form.

HIT Type 2

HIT type 2 is much more serious. It is an immune-mediated condition involving antibodies directed against complexes of heparin and platelet factor 4.

The antibodies activate platelets and create a strongly prothrombotic state. This means that even though the platelet count decreases, the patient is at increased risk for thrombosis.

Possible complications include:

• Deep venous thrombosis
• Pulmonary embolism
• Myocardial infarction
• Stroke
• Limb ischemia
• Skin necrosis
• Organ thrombosis
• Gangrene

Note: HIT type 2 often develops several days after heparin exposure but may occur rapidly in a patient with previous heparin-dependent antibodies. A platelet decrease greater than approximately 50% from baseline is particularly concerning.

Management of HIT

When clinically significant HIT is suspected, heparin should be discontinued. This includes eliminating avoidable exposure from sources such as heparinized catheter flushes.

Low-molecular-weight heparin should not automatically be substituted because HIT antibodies can cross-react with LMWH.

Alternative anticoagulants may include direct thrombin inhibitors such as:

• Argatroban
• Bivalirudin

Note: Fondaparinux may also be considered in selected clinical situations. Patients receiving ECMO who develop HIT may require conversion to another anticoagulant while extracorporeal support continues.

Protamine Sulfate

Protamine sulfate is used to reverse the anticoagulant effects of unfractionated heparin. Heparin carries a strong negative charge, while protamine carries a positive charge. When the two bind, they form an inactive complex.

A commonly described neutralizing dose is approximately 1 mg of protamine for each 100 units of heparin requiring reversal. The actual dose depends on how much heparin remains active in the patient’s circulation.

Because UFH has a short half-life, heparin administered several hours earlier may no longer require complete neutralization. Protamine should be administered slowly.

Rapid administration can cause:

• Hypotension
• Bradycardia
• Dyspnea
• Severe allergic reactions

Note: Excess protamine can itself interfere with coagulation and increase bleeding risk.

Reversal of Low-Molecular-Weight Heparin

Protamine is less effective against LMWH. It can neutralize some of the anticoagulant effect but does not completely reverse anti-factor Xa activity.

Only a portion of LMWH activity may be reversed. This is one reason unfractionated heparin may be preferred when rapid and complete reversal is especially important.

Heparin and Invasive Procedures

Because heparin interferes with clot formation, anticoagulation must be considered before invasive procedures. Procedures with increased bleeding risk may require temporary interruption of therapy.

Examples include:

• Bronchoscopy with biopsy
• Thoracentesis
• Arterial puncture
• Central venous catheter procedures
• Surgical procedures

Intravenous unfractionated heparin may sometimes be withheld for several hours before a procedure because of its short half-life.

LMWH generally requires a longer interval because its anticoagulant activity persists longer. The exact timing depends on the procedure, dosage, renal function, and individual bleeding risk.

Heparin and Arterial Puncture Safety

Patients receiving systemic anticoagulation may be at increased risk of hematoma following arterial puncture. After an arterial blood sample is obtained, direct pressure should be applied until hemostasis is achieved.

Patients receiving heparin may require longer compression than patients with normal coagulation. The clinician should also review coagulation status, platelet count, and relevant medications before performing an invasive puncture when significant bleeding risk is suspected.

Other Adverse Effects

Bleeding and HIT receive the most attention, but heparin may produce other adverse effects.

These may include:

• Hyperkalemia
• Osteoporosis with prolonged therapy
• Elevation of liver enzymes
• Injection-site hematoma
• Hypersensitivity reactions

Note: Elevated liver enzymes may occur during therapy but are often temporary and clinically insignificant. Long-term administration is more closely associated with complications such as osteoporosis.

Anti-inflammatory Effects of Heparin

Heparin has biological effects beyond anticoagulation. It has been described as having antiprotease and anti-inflammatory properties.

Heparin may interact with inflammatory mediators such as high-mobility group protein B1 and may reduce certain inflammatory processes. These effects have contributed to interest in potential respiratory applications involving inflammatory airway disease.

However, anticoagulation and bleeding remain important limitations when considering systemic heparin for conditions in which anticoagulation is not otherwise required.

Key Clinical Principles

Several principles help summarize the safe use of heparin.

• Heparin prevents formation and extension of blood clots but does not directly dissolve existing thrombi.
• Unfractionated heparin inhibits both thrombin and factor Xa through interaction with antithrombin.
• Low-molecular-weight heparin has proportionately greater activity against factor Xa and usually produces a more predictable anticoagulant response.
• Therapeutic intravenous unfractionated heparin commonly requires laboratory monitoring, while routine monitoring of LMWH is usually unnecessary.
• Bleeding is the most important immediate complication.
• Heparin-induced thrombocytopenia is a potentially life-threatening immune reaction characterized by falling platelet counts combined with an increased risk of thrombosis.
• Protamine sulfate can reverse unfractionated heparin but provides only partial reversal of LMWH.
• In respiratory care, heparin also has important procedural roles in arterial blood gas sampling, arterial catheter systems, ECMO, and selected cases of smoke inhalation injury.

Heparin Practice Questions

1. What is heparin?
Heparin is an anticoagulant medication that helps prevent the formation and extension of blood clots.

2. Does heparin directly dissolve an existing blood clot?
No. Heparin helps prevent an existing clot from becoming larger and reduces the formation of new clots, but it does not directly dissolve an established thrombus.

3. What naturally occurring protein is primarily responsible for the anticoagulant effects of heparin?
Antithrombin III

4. How does heparin enhance anticoagulation?
Heparin binds to antithrombin III and greatly accelerates its ability to inhibit important coagulation factors.

5. Which clotting factor is responsible for converting fibrinogen into fibrin?
Thrombin, also known as factor IIa.

6. What is the approximate anti-Xa-to-anti-IIa activity ratio of unfractionated heparin?
Approximately 1:1.

7. Why can unfractionated heparin inhibit thrombin effectively?
Its longer polysaccharide chains can bind both antithrombin III and thrombin simultaneously, allowing formation of a heparin-antithrombin-thrombin complex.

8. What is the approximate mean molecular mass of unfractionated heparin?
Approximately 12,000 Da.

9. How do low-molecular-weight heparins differ structurally from unfractionated heparin?
Low-molecular-weight heparins contain shorter polysaccharide chains and have a lower average molecular mass.

10. What are two examples of low-molecular-weight heparins?
Enoxaparin and dalteparin.

11. What is the approximate mean molecular mass of low-molecular-weight heparin?
Approximately 4,500 Da.

12. Why does low-molecular-weight heparin have less activity against thrombin than unfractionated heparin?
Its shorter polysaccharide chains are generally unable to bind thrombin and antithrombin III simultaneously.

13. What is the approximate elimination half-life of unfractionated heparin?
Approximately 30 to 60 minutes.

14. What is the approximate half-life of low-molecular-weight heparin?
Approximately 4 to 5 hours.

15. Why does low-molecular-weight heparin generally produce a more predictable anticoagulant response than unfractionated heparin?
It binds less extensively to plasma proteins and cellular components, resulting in more predictable bioavailability and anticoagulant activity.

16. Which laboratory test is commonly used to monitor therapeutic intravenous unfractionated heparin?
Activated partial thromboplastin time, or aPTT.

17. What aPTT range may be targeted during therapeutic unfractionated heparin administration?
Approximately 1.5 to 2 times the upper limit of the control value, depending on the laboratory and protocol.

18. Is aPTT routinely used to monitor low-molecular-weight heparin?
No. aPTT is not appropriate for routine monitoring of low-molecular-weight heparin.

19. Which laboratory measurement may be used when monitoring low-molecular-weight heparin is necessary?
Anti-factor Xa activity.

20. What is the most clinically significant adverse effect of heparin therapy?
Bleeding

21. What is heparin-induced thrombocytopenia?
Heparin-induced thrombocytopenia is a complication of heparin therapy characterized by a reduction in platelet count, with the immune-mediated form also causing an increased risk of thrombosis.

22. What is the major difference between HIT type 1 and HIT type 2?
HIT type 1 is generally a mild, early, transient decrease in platelets, while HIT type 2 is a serious immune-mediated reaction associated with thrombosis.

23. What protein is involved in the immune reaction responsible for HIT type 2?
Platelet factor 4.

24. Why can HIT type 2 be particularly dangerous despite the patient’s low platelet count?
HIT type 2 activates platelets and creates a prothrombotic state, so the patient can develop severe and potentially life-threatening blood clots despite thrombocytopenia.

25. What medication is used to reverse the anticoagulant effects of unfractionated heparin?
Protamine sulfate

26. What is the primary purpose of heparin therapy in acute venous thromboembolism?
To prevent further clot formation and extension while the body manages the existing thrombus.

27. What two major conditions are included under venous thromboembolism?
Deep venous thrombosis and pulmonary embolism.

28. How is unfractionated heparin commonly administered for acute venous thromboembolism?
An intravenous bolus followed by a continuous intravenous infusion.

29. How is low-molecular-weight heparin commonly administered?
By subcutaneous injection once or twice daily.

30. Why may anticoagulation be started before venous thromboembolism is fully confirmed?
Because untreated thromboembolic disease can progress rapidly and become life-threatening.

31. What is the main goal of heparin prophylaxis in hospitalized patients?
To reduce the risk of developing deep venous thrombosis and pulmonary embolism.

32. Name three hospitalized patient groups that may be at increased risk for venous thromboembolism.
Patients with critical illness, spinal cord injury, or previous venous thromboembolism.

33. What mechanical methods may be used to help prevent venous thromboembolism?
Early ambulation, compression stockings, intermittent pneumatic compression, and venous foot pumps.

34. When may mechanical prophylaxis be preferred over anticoagulant therapy?
When the patient has a significant bleeding risk or another contraindication to anticoagulation.

35. How can pulmonary embolism affect ventilation-perfusion relationships?
It reduces perfusion to ventilated lung regions, increasing physiologic dead space.

36. What acid-base abnormality may occur in a patient with pulmonary embolism who is hyperventilating?
Respiratory alkalosis

37. Why is heparin required during extracorporeal membrane oxygenation?
Because blood contact with artificial circuit surfaces activates coagulation and promotes clot formation.

38. What bedside test is commonly used to monitor anticoagulation during ECMO?
Activated clotting time, or ACT.

39. What ACT range may be used as a target during ECMO?
Approximately 160 to 200 seconds, depending on the protocol and clinical situation.

40. Name two factors other than heparin that can affect the ACT.
Examples include anemia, hypothermia, thrombocytopenia, hemodilution, and low fibrinogen.

41. Why are antithrombin III levels important during heparin therapy?
Heparin depends on adequate antithrombin III activity to produce its anticoagulant effect.

42. What may happen if a patient has low antithrombin III levels while receiving heparin?
The patient may appear resistant to heparin and require unusually high doses to achieve adequate anticoagulation.

43. Why is heparin used in arterial blood gas syringes?
To prevent the blood specimen from clotting before analysis.

44. Why is dry or lyophilized heparin generally preferred for arterial blood gas sampling?
It prevents clotting while minimizing dilution of the blood specimen.

45. What can happen if too much liquid heparin remains in an arterial blood gas syringe?
The specimen may become diluted, causing inaccurate blood gas measurements.

46. How can excessive liquid heparin affect PCO₂ in a blood gas sample?
It can decrease the measured PCO₂.

47. Why should a heparinized blood gas specimen be mixed after collection?
To distribute the anticoagulant evenly and prevent clot formation within the sample.

48. Why is a waste sample often withdrawn before collecting blood from an arterial catheter?
To clear flush solution from the catheter and reduce contamination of the analytical specimen.

49. What is one reason heparinized saline may be used in an arterial monitoring system?
To help maintain catheter patency and reduce clot formation within the line.

50. Why should unnecessary heparin exposure from vascular flush solutions be minimized?
Because additional heparin exposure may increase the risk of complications such as heparin-induced thrombocytopenia.

51. What is the approximate neutralizing dose of protamine sulfate for unfractionated heparin?
Approximately 1 mg of protamine for every 100 units of heparin requiring reversal.

52. Why should protamine sulfate be administered slowly?
Rapid administration can cause hypotension, bradycardia, dyspnea, and other serious reactions.

53. What is the commonly described maximum protamine dose per administration?
Approximately 50 mg per dose.

54. Can protamine sulfate completely reverse the effects of low-molecular-weight heparin?
No. Protamine only partially reverses the anticoagulant activity of low-molecular-weight heparin.

55. Approximately how much of low-molecular-weight heparin antifactor Xa activity may be reversed by protamine?
About 60%.

56. Why may unfractionated heparin be preferred when rapid reversal might be necessary?
It has a short half-life and can be reversed more effectively with protamine sulfate.

57. What adverse effect may occur with prolonged heparin therapy involving the bones?
Osteoporosis

58. What electrolyte abnormality has been associated with heparin therapy?
Hyperkalemia

59. What liver-related laboratory abnormality may occur during heparin treatment?
Elevation of liver enzyme levels.

60. Are elevated liver enzymes from heparin usually associated with major liver injury?
No. They are generally described as benign and not associated with significant hepatic complications.

61. Why should low-molecular-weight heparin not be substituted for unfractionated heparin in a patient with HIT?
Because HIT antibodies can cross-react with low-molecular-weight heparin.

62. What are two direct thrombin inhibitors that may be used when heparin must be discontinued because of HIT?
Argatroban and bivalirudin.

63. What selective anticoagulant may also be considered in some patients with HIT?
Fondaparinux

64. What is white clot syndrome?
A severe thrombotic complication associated with immune-mediated heparin-induced thrombocytopenia.

65. What are two possible complications of white clot syndrome?
Pulmonary embolism and stroke.

66. When does immune-mediated HIT commonly develop after starting heparin?
Approximately 6 to 12 days after therapy begins.

67. Why can HIT develop sooner in a patient who has previously received heparin?
Preexisting heparin-dependent antibodies may trigger a rapid immune response.

68. What degree of platelet decline should raise concern for HIT?
A decrease of more than approximately 50% from the baseline platelet count.

69. What should be done if significant HIT is suspected?
Heparin should be discontinued and an alternative anticoagulant should be considered.

70. Why may heparin need to be withheld before an invasive procedure?
Because its anticoagulant effect increases the risk of procedural bleeding.

71. About how long may intravenous unfractionated heparin be withheld before certain bronchoscopy procedures?
Approximately 2 to 6 hours, depending on the procedure and clinical situation.

72. About how long may low-molecular-weight heparin need to be withheld before a higher-risk invasive procedure?
Approximately 24 hours, depending on factors such as renal function and bleeding risk.

73. Why may renal function affect the timing of low-molecular-weight heparin before a procedure?
Impaired renal function can prolong the drug’s anticoagulant effect.

74. What should be done after an arterial puncture in a patient receiving heparin?
Firm direct pressure should be applied until hemostasis is achieved, often for longer than in a non-anticoagulated patient.

75. Why can a partially clotted arterial catheter produce inaccurate blood pressure readings?
The clot can dampen the arterial pressure waveform and interfere with accurate pressure transmission.

76. What is the purpose of using aerosolized heparin in smoke inhalation injury?
To help reduce fibrin-related airway obstruction and limit formation of obstructing airway casts.

77. What medication is commonly combined with aerosolized heparin in smoke inhalation injury to help break down thick mucus?
N-acetylcysteine

78. Why may bronchodilators be added to aerosolized heparin therapy in smoke inhalation injury?
To treat associated bronchospasm and improve airflow.

79. What types of airway material can accumulate after severe smoke inhalation?
Fibrin, thick secretions, cellular debris, and airway casts.

80. How can fibrin casts affect breathing?
They can obstruct the airways, increase airway resistance, impair ventilation, and worsen gas exchange.

81. What is the purpose of heparinized capillary tubes in neonatal or pediatric blood sampling?
To prevent the small blood specimen from clotting before analysis.

82. Why are capillary blood gas samples less useful for evaluating oxygenation?
Capillary samples do not reliably reflect arterial oxygen tension.

83. What is one major reason repeated arterial-line blood sampling can contribute to anemia?
Frequent removal and discarding of blood can result in cumulative blood loss.

84. Why should the amount of blood discarded from an arterial line before sampling be minimized?
To reduce unnecessary blood loss while still clearing the catheter dead space.

85. What may happen if a blood gas specimen is not adequately mixed with heparin?
Small clots may form and interfere with laboratory analysis.

86. How can room air contamination affect a blood gas specimen?
It can increase the measured PO₂ and decrease the measured PCO₂.

87. Why can heparinized flush solution contaminate a blood gas specimen drawn from an arterial catheter?
Residual flush solution can mix with the blood and dilute the sample.

88. What is the purpose of a pressurized flush system connected to an arterial catheter?
To maintain catheter patency and prevent blood from backing up into the line and clotting.

89. Why should a clot at the tip of an arterial catheter not be forcefully flushed into the circulation?
The clot could become an embolus and obstruct blood flow elsewhere.

90. What should be considered before performing an arterial puncture on a patient receiving heparin?
The patient’s bleeding risk, coagulation status, platelet count, and ability to achieve hemostasis.

91. Why may a patient receiving heparin require longer pressure at an arterial puncture site?
Heparin slows clot formation and may prolong bleeding.

92. How does heparin help reduce thromboembolic complications in atrial fibrillation?
It decreases the formation and extension of thrombi that may develop because of blood stasis in the atria.

93. Why can atrial fibrillation increase the risk of embolic complications?
Disorganized atrial contractions can allow blood to stagnate and form clots.

94. What is the role of heparin in NSTEMI treatment?
It may be used as antithrombin therapy to reduce further clot formation in the coronary circulation.

95. Is fibrinolytic therapy the same as heparin therapy?
No. Fibrinolytic drugs break down fibrin in existing clots, while heparin primarily prevents new clot formation and clot extension.

96. Why is intravenous heparin inappropriate for uncontrolled active bleeding?
It prolongs clotting and can worsen hemorrhage.

97. What should happen to heparin therapy if serious bleeding develops?
The heparin should be stopped and the patient should be evaluated for reversal and supportive treatment as needed.

98. Why can excessive protamine sulfate itself increase bleeding risk?
Protamine can have anticoagulant effects when given in excessive amounts.

99. What anti-inflammatory property has been associated with heparin?
Heparin has been described as having antiprotease and anti-inflammatory activity in addition to its anticoagulant effects.

100. What is the central safety principle when using heparin?
The dose and monitoring must balance prevention of unwanted clot formation against the risk of excessive bleeding.

Final Thoughts

Heparin is an important anticoagulant with applications that extend across respiratory care, critical care, cardiovascular medicine, vascular monitoring, and laboratory testing. Its primary action is to enhance antithrombin activity and inhibit key coagulation factors, particularly thrombin and factor Xa.

Unfractionated heparin and low-molecular-weight heparin differ in molecular structure, pharmacokinetics, monitoring requirements, and reversibility. Safe therapy requires balancing prevention of unwanted thrombosis against the risk of hemorrhage.

Clinicians must also recognize heparin-induced thrombocytopenia, understand appropriate laboratory monitoring, and use careful technique when heparin is involved in arterial blood sampling or extracorporeal support.